Celcuity Inc. (CELC)

16,77 -0,06 (-0,36%) Al cierre: 04:00PM EDT

Celcuity Inc.

16305–36th Avenue North
Suite 100
Minneapolis, MN 55446
United States
763 392 0767
https://www.celcuity.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 55

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Brian F. Sullivan	Co-Founder, Chairman & CEO	478,12k	N/A	1962
Dr. Lance G. Laing Ph.D.	Co-Founder, Chief Science Officer, VP, Secretary & Director	389,55k	N/A	1962
Ms. Vicky Hahne	Chief Financial Officer	281,59k	N/A	1966
Dr. John R. MacDonald Dabt, Ph., Ph.D.	Senior Vice President of R&D	N/A	N/A	1955
Ms. Sheri Smith	Acting Head of Clinical Operations	N/A	N/A	N/A
Mr. Igor Gorbatchevsky M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Eldon C. Mayer III, M.B.A.	Chief Commercial Officer	N/A	N/A	1961

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Gobierno corporativo

El ISS Governance QualityScore de Celcuity Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 7; Tablero: 9; Derechos de los accionistas: 6; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.